No­var­tis to re­sume the pro­duc­tion of two ra­di­oli­gand ther­a­pies af­ter re­solv­ing qual­i­ty is­sues

Ear­li­er this year, No­var­tis tout­ed its ra­di­oli­gand as a ma­jor piece to counter com­pe­ti­tion in the can­cer space. How­ev­er, the phys­i­cal pro­duc­tion of its prod­ucts has had any­thing but a smooth ride.

In May, No­var­tis had to sus­pend pro­duc­tion of Lu­tathera and Plu­vic­to, its two pri­ma­ry ra­dio­ther­a­pies. Ac­cord­ing to the com­pa­ny, this was done out of an abun­dance of cau­tion as a re­sult of po­ten­tial qual­i­ty is­sues iden­ti­fied in its man­u­fac­tur­ing. The pro­duc­tion sus­pen­sion im­pacts the com­mer­cial and clin­i­cal tri­al sup­ply of the prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER